News
CRBP
10.15
-10.18%
-1.15
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 10.2%, Underperforms Competitors
Dow Jones · 1d ago
Weekly Report: what happened at CRBP last week (0127-0131)?
Weekly Report · 5d ago
Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
TipRanks · 01/31 11:48
Weekly Report: what happened at CRBP last week (0120-0124)?
Weekly Report · 01/27 10:45
Bearish Sentiment Across The Cannabis Space - Check Full Movers For January 20, 2025
Benzinga · 01/20 20:30
Weekly Report: what happened at CRBP last week (0113-0117)?
Weekly Report · 01/20 10:39
Weekly Report: what happened at CRBP last week (0106-0110)?
Weekly Report · 01/13 10:40
Corbus Pharmaceuticals Announces That Clinical Data For CRB-701 From Western Dose Escalation Study To Be Presented At ASCO GU 2025
Benzinga · 01/08 13:21
Corbus Pharmaceuticals announes data for CRB-701 from Western Dose study
TipRanks · 01/08 13:16
Weekly Report: what happened at CRBP last week (1230-0103)?
Weekly Report · 01/06 10:46
Weekly Report: what happened at CRBP last week (1223-1227)?
Weekly Report · 12/30/2024 10:41
Weekly Report: what happened at CRBP last week (1216-1220)?
Weekly Report · 12/23/2024 10:46
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), Corbus Pharmaceuticals (CRBP) and Fortrea Holdings Inc. (FTRE)
TipRanks · 12/17/2024 10:30
Weekly Report: what happened at CRBP last week (1209-1213)?
Weekly Report · 12/16/2024 10:47
Promising Potential of Corbus Pharmaceuticals: Buy Rating Reinforced by Key Assets and Strategic Focus
TipRanks · 12/12/2024 07:15
Corbus Pharmaceuticals Advances Oncology Research with First Patient Dosed in CRB-601 Clinical Trial for Advanced Solid Tumors
Barchart · 12/09/2024 16:18
Corbus Pharmaceuticals announces dosing of first patient in FIH study of CRB-601
TipRanks · 12/09/2024 12:32
CORBUS PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT IN ITS FIRST-IN-HUMAN STUDY OF CRB-601 TO TREAT PATIENTS WITH ADVANCED SOLID TUMORS
Reuters · 12/09/2024 12:00
Weekly Report: what happened at CRBP last week (1202-1206)?
Weekly Report · 12/09/2024 10:46
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential
Barchart · 12/08/2024 06:00
More
Webull provides a variety of real-time CRBP stock news. You can receive the latest news about Corbus Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.